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Abstract 
Detection of AmpC β-lactamases (AmpC-bls) is important for infection control purposes and 
therapeutic options. Here, we provided a diagnostic anti β-lactamase neutralization test (bla-NT); 
modified from broth microdilution (BM) for the detection of bls-AmpC, CMY, in multidrug 
resistant Escherichia coli and Klebsiella pneumoniae. Anti-bla neutralizing activity against these 
two bacteria was tested. Anti bla-CMY was prepared in rabbits and used in: bla-NT; 
investigating effect on bacterial colony forming unit (CFU); and in ELISA. In bla-NT, the anti-
bla-CMY neutralized exocellular bls produced by the tested bacterial strains and resulted in an 
increase in the bacterial sensitivity to the tested antimicrobials and reduction in minimum 
inhibitory concentration.  Interestingly, the anti-bla-CMY decreased the CFU and its morphology 
when added to the tested bacteria. ELISA-OD was significantly correlated with the drop in 
minimum inhibitory concentration and CFU counts at P-value ≤ 0.05 and 0.01, respectively. It 
could be concluded that, bla-NT could detect bls-AmpC and run parallel to BM in microbiology 
laboratory. Investigations are running to develop the test for quantitative detection of bls-AmpC.  
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Introduction 
 AmpC β-lactamases is β-lactmase 
antibiotics destroying enzyme that has a 
special clinical interest since late 1980s. It is 
associated with multiple antibiotic resistance 
to cephalothin, cefazolin, cefoxitin, most 
penicillins and bla- inhibitor/β-lactam 
combinations. Bls enzymes over expression 
confer resistance to broad-spectrum 
cephalosporins including cefotaxime, 
ceftazidime, and ceftriaxone [1]. The plasmid-
determined enzymes are related, sometimes 
very closely to chromosomally determined bls-
AmpC. Several varieties from the following 
enzymes, CMY, FOX, ACC, LAT, MIR, 
ACT, MOX and DHA were detected [2-4]. 
Escherichia coli and Klebsiella pneumoniae 
have a great concern when produce Extended 
Spectrum β-Lactamases (ESBLs) associated 
with plasmid mediated bls-AmpC, which 
should be taken seriously and should be early 
diagnosed in clinical laboratory. Therefore, it 
is essential that clinical laboratories accurately 
detect strains producing bls-AmpC [5]. There 
are presently no Clinical and Laboratory 
Standards Institute (CLSI) or other approved 
criteria for bls-AmpC detection [6].  
Some Gram-negative bacteria producing 
both AmpC and ESBL give positive results in 
ESBL screening test but fail the confirmatory 
test involving increased sensitivity with 
clavulanic acid [7,8]. This phenotype give 
false positive results in stains producing high 
level bla TEM-1, OXA-type ESBLs and 
carbapenemases and that with complex 
mutation of TEM [9]. Cefoxitin resistance for 
detection of AmpC enzymes is not specific 
since cefoxitin resistance can also be produced 
by certain carbapenemases [10], few classes 
A- bla [11] and by decreased levels of 
production of outer membrane porins in both 
K. pneumoniae and E. coli [12]. Limited 
results interpretation in the aforementioned 
techniques was recorded. Meanwhile, 
detection by antibody based methods was used 
with success. Specific antibodies against β-
lactamases can neutralize the enzyme reaction 
and neutralization tests have led to 
classification of β-lactamases of Gram-
negative bacteria into different classes [13-15]. 
ELISA and immunoblotting could screen and 
quantify AmpC, SHV and TEM bls with high 
sensitivity and specificity. In addition, ELISA 
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can permit careful study of the effects of point 
mutations on bls and exploration of issues of 
induction and regulatory mechanisms affecting 
bls production [16-19]. ELISA is costly and 
laborious and could not be routinely used for 
the detection of bls in clinical laboratories, in 
addition, DNA based methods does not always 
indicate enzyme production. 
In the present work, we provide bla-NT as 
modified test from broth microdilution test for 
accurate detection of bls-AmpC and for 
determining the possible activity on the 
multidrug resistant bacterial strains.  
Material and methods 
Bacterial isolates 
Eighty-eight samples were collected from 
different sources. The samples included 
nineteen human urine samples; 19 specimens 
from livers of freshly dead broilers and 50 
diarrheic fecal samples from sheep. Samples 
were inoculated onto MacConkey's and Eosine 
Methylene Blue agar media (Oxoid, UK) and 
then incubated at 37ºC for 24 h. Isolates were 
identified to the species level with API 20E 
system (BioMe´rieux, Marcy l’Etoile, France. 
An E. coli control positive strain (code No. 
HE1) was previously known as bla-CMY 
producer after testing with the specific primers 
[20]. Periplasmic extracts of these strains were 
used for the preparation of anti-CMY serum in 
rabbits. It was kindly supplied by 
Microbiology Department, Faculty Veterinary 
Medicine, Zagazig University, Egypt.   
Extraction of β-lactamases 
Periplasmic extracts were prepared from E. 
coli and K. pneumoniae as previously 
described [21]. Briefly, the bacterial strains 
were inoculated into tryptic soya broth with 
ampicillin at concentration of 100 mg/L, 
incubated at 37ºC for 24 h. At the end of 
incubation period; bacterial sediments were 
centrifuged at 3000 r.p.m. for 15 min. 
Bacterial pellets were suspended in 500 µL 
(Tris HCl, 50 mM, pH 7.4) and 2 µL of 
lysozyme solution (40 mg/mL) for 30 min. 
Periplasmic crude extracts were obtained after 
14,000 r.p.m for 15 min. Periplasmic extracts 
protein concentration of the test and control 
strains were determined (0.66-1.04 mg/ml) and 
the extracts were examined for 38 KD band by 
sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis.  
Production of anti-β-lactamases polysera in 
rabbits  
Polyclonal antisera against periplasmic 
extracts containing bla-CMY were produced in 
rabbits [18], these extracts were obtained from 
the E. coli control strain (code No. HE1) 
previously known and confirmed as bla-CMY 
producer. Four female New Zealand white 
rabbits each weighing approximately 1.5 kg 
were used in the study. Three rabbits were 
injected in multiple sites I.M and S.C with one 
mL complete Freund’s adjuvant (CFA) and 
periplasmic extract with protein content at 
concentration of 500 g and one rabbit 
received CFA and served as control. One week 
from the initial dose, rabbits were given two 
booster doses each of one mL incomplete 
Freund’s adjuvant containing 250 g 
periplasmic extract at interval of 2 weeks in 
between each injection. A final dose of 100 g 
purified extract suspended in sterile PBS was 
injected I.V. The control rabbit was injected at 
the same intervals with sterile PBS during the 
course of experiment. Anti-bls polysera 
development was monitored before each 
inoculation by double immunodiffusion [21]. 
Two weeks after the final injection, the four 
rabbits were bled, blood was collected and the 
sera were harvested. Sera were heat-
inactivated, divided into aliquots and stored at 
-20ºC. 
Disc diffusion 
 Resistance phenotypes were detected using 
β-lactam antibiotic discs: amoxicillin (25 µg), 
amoxicillin/ clavulanate (3/30), cephalexin (30 
µg), aztreonam (30 µg), cefuroxime (30 µg), 
cefepime (30 µg), cefotaxime (30 µg), 
ceftriaxone (30 µg), ceftazidime (30 µg), 
cefoxitin (30 µg), imipenem (10 µg) and 
piperacillin (75 µg). Strains with multiple 
resistances to β-lactams were included in this 
study. Zone size interpretation of antimicrobial 
agents was according to Clinical Laboratory 
Standards Institute (CLSI) M100-S24 [22]. 
Broth microdilution (BM) 
Broth microdilution was run as previously 
done [23], 100 µL of serial double-fold 
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dilution of ceftazidime in MHI were added to 
equal amount of MHI containing 2.5 X 106 
CFU/mL of the examined strains. Microtiter 
plates were incubated for 18 h at 35ºC. MIC of 
ceftazidime and CFU counts in each MIC well 
were examined. 
β-lactamase neutralization test (bla-NT) 
 β-lactamase neutralization test is a 
modified broth microdilution. We 
hypothesized that rabbit polysera containing 
anti-bla-CMY added in the test vicinity may 
neutralise the produced AmpC-bls by the 
bacteria under the test conditions and may 
protect the β-lactam (ceftazidime) in the test 
conditions, and hence may raise sensitivity of 
that bacteria to the β-lactam leading to 
detectable decrease in MIC. Briefly, 100 µL of 
serial double-fold diluted ceftazidime in 
Muller Hinton broth (MH) were added to 
equal amounts of MH containing 2.5 X 106 
CFU/mL of the examined bacteria. After being 
mixed well, 10 µL of rabbit polysera 
containing anti-bla-CMY were added to each 
well. Control positive wells without polysera 
and contain instead 10 µL periplasmic bls 
extracts (0.01 mg to each well of the assay) 
were included. Microtiter plates were 
incubated for 18 h at 35ºC. MIC of ceftazidime 
and CFU counts in each MIC well were 
detected. 
 Percent drop of ceftazidime MIC and CFU 
counts in bla-NT were calculated as follows: 
- % drop of ceftazidime MIC= Ceftazidime 
MIC in BM - ceftazidime MIC in bla-NT/ 
ceftazidime MIC in BM X100. 
- % drop of CFU counts = CFU counts in MIC 
well of BM - CFU counts in MIC wells of bla-
NT/ CFU counts in MIC well of BM X100. 
 Indirect ELISA         
Indirect ELISA was done according to the 
protocol of Tijssen [23]. Ninety-six-well 
immunoassay plates (Fisher) were coated 
overnight with 2 μg/mL of periplasmic 
extracts of the examined strains suspended in 
fresh carbonate-bicarbonate buffer (pH 9.6). 
Plates were washed 3x times with PBS 
containing 0.05% tween 20, and then blocked 
with 5% bovine serum albumin in PBS for 2 h. 
Sera dilutions of immunized and non-
immunized rabbits were done and 100 µL/well 
were added from each dilution and the plates 
were incubated for 2 h at room temperature. 
After being washed 3x in PBS, diluted horse 
radish peroxidase (HRP) conjugated goat-anti-
rabbit IgG (KPL, San Antonio, CA, USA) was 
added at volume of 100 µL/well in PBS and 
the plates were incubated for an hour. 
Checkerboard titration of primary antibody 
and conjugate was done to determine OD 
values of periplasmic extracts. Plates were 
incubated with ABTS substrate solution for 
15-45 min at room temperature, color 
development was terminated by the addition of 
0.5 M of H2SO4. OD was determined at 405 
values using ELISA plate reader (Cerus 
Corporation, CA, U.S.A). 
Results 
Strains resistance profile to β-lactams 
E. coli and K. pneumoniae were resistant to 
amoxicillin, amoxicillin/ clavulanate, aztreo-
nam, cephalexin, cefuroxime, cefotaxime, 
ceftriaxone and cefoxitin, with variable resist-
ance to piperacillin and cefepime according to 
disc diffusion. All strains isolated from 
chickens, sheep and humans were extremely 
resistant to β- lactams, and they were resistant 
to seven or more of β- lactams but sensitive to 
ceftazidime and imipenem.  Except an E. coli 
isolated from human, all the strains were 
resistant to cefepime. All strains were sensitive 
to ceftazidime, therefore, this antimicrobial 
was used in bla-NT and broth microdilution 
(Table 1).  
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Table 1: Minimal inhibitory concentrations (MIC) of ceftazidime (CAZ) in β-lactamase neutralization test 
(Bls NT) and broth microdilution (BM) against  E. coli  and  K. pneumoniae resistant phenotypes 
Strain 
Strain 
source 
Strain 
code 
β-lactam 
resistant phenotype 
BM bls NT 
 
CAZ 
MIC 
 
CAZ 
MIC 
% drop in 
CAZ 
MIC 
CFU 
counts 
E. coli 
Human 
HE1* AX,AMC,CL,CXM,CTX,CRO,FOX,AZ, PRL 1.0 0.125 87.5 100 
HE6 AX,AMC,CL,CXM,CTX,FOX,AZ 4.0 0.50 87.5 100 
Broiler 
BE1 
AX,AMC,CL,CXM,CTX,CRO, FOX,AZ, 
PRL, FEB 
1.0 0.25 87.5 100 
BE12 
AX,AMC,CL,CXM,CTX,CRO, FOX,AZ, PRL, 
FEB 
2.0 0.50 75.0 100 
BE18 AX,AMC,CL,CXM,CTX,CRO,FOX,AZ, FEB 1.0 0.25 87.5 100 
Sheep SE12 
AX,AMC,CL,CXM,CTX,CRO,FOX,AZ, PRL, 
FEB 
0.25 0.125 50.0 40 
K. 
pneumoniae 
Human 
HK1 AX,AMC,CL,CXM,CTX,CRO,FOX,AZ 1.0 0.50 
50.0 
50 
HK3 
AX,AMC,CL,CXM,CTX,CRO,FOX,AZ, PRL, 
FEB 
0.5 0.25 
50.0 
40 
HK6 
AX,AMC,CL,CXM,CTX,CRO,FOX,AZ, PRL, 
FEB 
1.0 0.50 
50.0 
66 
HK7 AX,AMC,CL,CXM,CTX,CRO,FOX,AZ, FEB 0.5 0.25 
50.0 
50 
* = Control positive strain    E. coli standard strain.    AX: amoxicillin, AMC: amoxicillin/clavulanate, CL: 
cephalexin, AZ:aztreonam, CAZ:ceftazidime,  CXM:cefuroxime,  CTX: cefotaxime, CRO: ceftriaxone, 
FEP:cefepime , FOX:cefoxitin, PRL: piperacillin. 
 
β-Lactamases were detected in the tested 
antibiotics resistant bacteria   
Periplasmic extracts of the tested and 
control strains were examined for bla-CMY.  
A band of 38 KD was seen which is 
characteristic for CMY β-lactamase and was at 
the same level of the standard and the positive 
control (Figure 1A).                                                  
Neutralization of exocellular β-lactamases 
in bla-neutralization test 
Anti-bla CMY reduced the MIC of the 
multidrug resistant strains  
Anti-bla-CMY sera neutralizing activity 
against E. coli and K. pneumoniae strains 
confirmed that they are multidrug resistant. 
MIC of ceftazidime was detected in bla-NT 
and broth microdilution (Table 1). MIC of 
ceftazidime against the E. coli and K. 
pneumoniae bacterial strains ranged 0.25-4.0 
µg/mL and 0.125-1.0 µg/mL, respectively, in 
broth microdilution. The anti-CMY-bla 
neutralized exocellular β-lactamases produced 
from the bacteria under the induced 
ceftazidime conditions in bla-NT test raised 
sensitivity of the bacteria to ceftazidime with 
50-87.5% drop of ceftazidime MIC. Control 
wells with periplasmic extracts instead of 
polysera showed raised ceftazidime MIC 1-2-
fold among the examined strains (Table 1). 
Anti-bla CMY reduced the bacterial colony 
forming units (CFU) 
Colony counts were determined in the anti-
CMY treated wells. Interestingly, a drop of 
CFU counts in MIC wells of bla-NT ranged 
40-100% (Table 1). The drop in the CFU was 
not restricted to the sample source where all 
the tested strains revealed drops in the CFU 
regardless their origin (Table 1).
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Figure 1: Molecular weight of the purified extracts.  After extraction of Bla-CMY and protein quantification, 
three tested periplasmic extracts showed 38 kb bands (2-4) that were comparable to the control (1).  
 
Anti-bla-CMY changed the bacterial colony 
phenotypes  
Subculture of the strains from MIC wells of 
bla-NT was done. After being cultured 
overnight, the bacterial colonies were 
examined. The bacterial colonies of the MIC 
antisera treated wells were pin point and flat 
colonies; meanwhile colonies from MIC wells 
of broth microdilution were normal elevated 
and circular (Figure 1B). The colonies were 
dense and pasty in exposed to anti-bla 
neutralizing sera compared with few and dry 
colonies of the same bacterial strain that not 
exposed to antisera.   
Correlation of indirect ELISA with bla-
neutralization test 
ELISA-OD of periplasmic extracts 
correlated with the results of bla-NT (Table 2). 
Correlation coefficient revealed strong direct 
correlation of ELISA with percent drop of 
both ceftazidime MIC and CFU counts in MIC 
wells of bla-NT. Correlation coefficient of 
0.725 and 0.796 with corresponding P-value 
less than 0.05 and 0.01 were detected, 
respectively. Moreover, CMY-bla produced 
from an E. coli strain isolated from sheep 
(code no. SE12) was only detected in bla-NT. 
Bla-OD value of this isolate was similar as that 
of negative control sample (Table 2). 
 
Table 2: ELISA-OD and parameters of β-lactamases neutralization test (Bls NT) for detection of CMY-β-
lactamases in E. coli and K. pneumoniae  
Method 
Strains code No. 
E. coli K. pneumoniae 
HE1* HE6 BE1 BE12 BE18 SE12 HK1 HK3 HK6 HK7 
ELISA O.D. 0.55 0.49 0.42 0.37 0.36 0.03 0.34 0.24 0.37 0.23 
Bls NT 
drop % of 
ceftazidime MIC 
87.5 87.5 87.5 75.0 87.5 50.0 50.0 50.0 50.0 50.0 
% drop of CFU 
counts 
100 100 100 100 100 40.0 50.0 40.0 66.0 50.0 
* = Control positive strain    O.D=optical density    
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Discussion 
Resistance due to plasmid mediated AmpC 
enzymes is less common than extended 
spectrum bls (ESBL) production in some parts 
of the world but may be both harder to detect 
and broader in spectrum. Other parts suffer 
from annual increased incidence of bls-AmpC 
in E. coli and causing mainly urinary tract 
infections in older women [24]. Detection of 
plasmid-mediated AmpC-bls by three-
dimensional test, cefoxitin agar method, clover 
leaf test, and double-disk test have 
disadvantages of difficult results interpretation 
[25]. Currently, there are no recommendations 
available from the CLSI for detection of 
organisms producing plasmid-mediated 
AmpC-bls where many bls-AmpC producers 
are not resistant to broad spectrum 
cephalosporins by CLSI breakpoints. Yet, 
adverse clinical outcomes occur in these 
patients when treated with cephalosporins 
[20]. In vicinity of bla-NT, anti-CMY-bla 
neutralized the lactamases produced by the 
bacteria under test, therefore, the sensitivity of 
the bacteria to ceftazidime with drop of 
ceftazidime-MIC and CFU counts in MIC 
wells of bla-NT raised. In the present work, E. 
coli and K. pneumoniae strains were resistant 
to cefoxitin and clavulanate, some of them 
were resistant to cefepim but sensitive to 
ceftazidime and imipenem (Table 2).  
 
 
Figure 2: Bacterial colony shape after subculture from MIC wells. Right plate show normal circular pasty 
colonies (control), left plate show pin point colonies after to neutralization of β-lactamses by anti-CMY serum 
in vicinity of bla neutralization test. 
 
This antibiogram might be an indicator for 
bls-AmpC, in addition, anti CMY polyserum 
used in bla-NT was raised against bls with 
molecular weight 38 kb, these bls were 
obtained from PCR confirmed CMY-bla 
producing strain [1,15]. Anti-bla CMY used in 
bla-NT does not crossly react with other 
lactamases. Previously, no cross-reactivity of 
the anti-CMY-2 antibody was seen against 
TEM-1, SHV-1, K-1, or OXA- bla but 
polyclonal rabbit anti-bla CMY-2 could detect 
CMY-2, P99 and ACT-1 by ELISA [25]. 
Antibody based methods depended previously 
on extracted periplasmic bls from bacterial 
periplasm [18,26], and it was suggested that 
level β-lactamase expression due to either 
promoter mutations or gene copy number 
which may affect the ability of bla-SHV 
detection in Gram-negative bacilli using 
fluorescein-labeled anti-bodies [27]. 
Meanwhile, in this work, exocellular bls-
AmpC were encoded and expressed 
sufficiently from bacteria under the conditions 
of bla-NT and then detected by specific 
polyserum. There was a strong direct 
correlation 0.725 of bla-NT with indirect 
ELISA, in addition, β-lactamases were 
expressed sufficiently in bla-NT vicinity that 
lead to AMPC-bla was detected in one more 
 
 
49 
isolate (code No.SE12, Table 2). PCR is the 
"gold standard" for the identification of only 
bla genes but could not detect expressed 
enzymes, in addition, PCR/sequencing is less 
feasible [28]. AmpC-bls expression screening 
could be detected by bla-NT. By extension, 
there will be interest to develop bla-NT 
quantitative detection of produced bls-AmpC 
and improve antibody-antigen combination in 
the test vicinity. ELISA could detect 
picograms of lactamases in periplasmic 
extracts of Gram-negative bacteria, 
meanwhile, ELISA is not routinely used to 
study clinical samples because they are 
expensive and time consuming. Bla-NT could 
be used routinely in microbiology laboratory 
and go parallel to standardized broth 
microdilution.   
Conclusion 
AmpC-bls produced from E. coli and K. 
pneumoniae strains could be detected by anti-
CMY-bla added in vicinity of bla 
neutralization test. Results of bla-NT correlate 
with ELISA-OD. More AmpC producing 
strains could be detected due to sufficient 
expression of lactamases in bla-NT test 
conditions, therefore, it could be run parallel to 
standardized broth microdilution in clinical 
microbiology laboratory. Further work is 
required for quantitative detection of bls-
AmpC and gene expression in Gram negative 
bacteria.  
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 الملخص العربي
 CpmA نزيماتإلتحديد مفرازات  YMCنزيمات إاستخدام مضادات 
 عادل عطيه محمد احمد، إيمان عبد الفتاح و جمال عبد المنعم المولد*
 جامعة الزقازيق-كلية الطب البيطري -قسم الميكروبيولوجيا 
ت. وفي هذا البحث تم معادله هذه الانزيمات في تجربه نزيمات بيتا لاكتاماز ذو اهميه في العلاج والسيظره علي الوبائياإتحديد 
وذلك لتحديد  noitulidorcim htorb بطريقه الشوربه المخففه  )TN-alB(معدله من اختبار الحساسيه للمضادات الحيويه 
تخدامها في تقنيه هذه الانزيمات في ميكروبي الكولاي القولوني والكليبسيلا وتم تحضير مضادات الانزيمات في الارانب ليتم اس
الاليزا وفي هذا الاختبار ولقد اظهرت النتائج ان الانزيمات الناتجه في محيط الاختبار تم معادلتها واصبح الميكروب اكثر 
حساسيه للمضاد الحيوي المضاف في محيط الاختبار مع نقص في قيمه الادني المثبط وقد كانمت نتائج الاليزا مؤكده لهذه 
ومما سبق نستنتج ان التجربه المعدله من اختبار الشوربه  10.0 , 50.0 ≤ eulav-Pالمعدل الاحصائي النتائج وذلك في 
المخفف يمكن ان تستخدم في معامل التشخيص لتحديد انواع البيتا لاكتاماز وذلك علي التوازي مع اختبارات الحساسيه 
 .للمضادات الحيويه الدارجه
 
